Table of Contents Author Guidelines Submit a Manuscript
International Journal of Hepatology
Volume 2014, Article ID 723868, 6 pages
http://dx.doi.org/10.1155/2014/723868
Research Article

IFNL4 ss469415590 Variant Is Associated with Treatment Response in Japanese HCV Genotype 1 Infected Individuals Treated with IFN-Including Regimens

1Departments of Gastroenterology and Nephrology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8677, Japan
2Department of Molecular Virology, Graduate School of Medicine, Chiba University, Chiba 260-8677, Japan
3Department of Gastroenterology, Kikkoman General Hospital, Noda 278-0005, Japan

Received 17 July 2014; Accepted 24 November 2014; Published 8 December 2014

Academic Editor: Shigeru Marubashi

Copyright © 2014 Tatsuo Miyamura et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. M. Di Bisceglie, “Hepatitis C and hepatocellular carcinoma,” Hepatology, vol. 26, no. 3, supplement 1, pp. 34S–38S, 1997. View at Google Scholar
  2. J. W. Ward, “The epidemiology of chronic hepatitis C and one-time hepatitis C virus testing of persons born during 1945 to 1965 in the United States,” Clinics in Liver Disease, vol. 17, no. 1, pp. 1–11, 2013. View at Publisher · View at Google Scholar · View at Scopus
  3. I. Saito, T. Miyamura, A. Ohbayashi et al., “Hepatitis C virus infection is associated with the development of hepatocellular carcinoma,” Proceedings of the National Academy of Sciences of the United States of America, vol. 87, no. 17, pp. 6547–6549, 1990. View at Publisher · View at Google Scholar · View at Scopus
  4. T. Kanda, F. Imazeki, and O. Yokosuka, “New antiviral therapies for chronic hepatitis C,” Hepatology International, vol. 4, no. 3, pp. 548–561, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. T. Kanda, O. Yokosuka, and M. Omata, “Treatment of hepatitis C virus infection in the future,” Clinical and Translational Medicine, vol. 2, article 9, 2013. View at Publisher · View at Google Scholar
  6. D. Ge, J. Fellay, A. J. Thompson et al., “Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance,” Nature, vol. 461, no. 7262, pp. 399–401, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. V. Suppiah, M. Moldovan, G. Ahlenstiel et al., “IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy,” Nature Genetics, vol. 41, no. 10, pp. 1100–1104, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. Y. Tanaka, N. Nishida, M. Sugiyama et al., “Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C,” Nature Genetics, vol. 41, no. 10, pp. 1105–1109, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. T. Miyamura, T. Kanda, S. Nakamoto et al., “Roles of ITPA and IL28B genotypes in chronic hepatitis C patients treated with peginterferon plus ribavirin,” Viruses, vol. 4, no. 8, pp. 1264–1278, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. M. Sugiyama, Y. Tanaka, T. Wakita, M. Nakanishi, and M. Mizokami, “Genetic variation of the IL-28B promoter affecting gene expression,” PLoS ONE, vol. 6, no. 10, Article ID e26620, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. T. Miyamura, T. Kanda, S. Nakamoto et al., “Hepatic STAT1-nuclear translocation and interleukin 28B polymorphisms predict treatment outcomes in hepatitis C virus genotype 1-infected patients,” PLoS ONE, vol. 6, no. 12, Article ID e28617, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. T. Kanda, X. Jiang, S. Nakamoto et al., “Different effects of three interferons L on toll-like receptor-related gene expression in HepG2 cells,” Cytokine, vol. 64, no. 2, pp. 577–583, 2013. View at Publisher · View at Google Scholar · View at Scopus
  13. L. Prokunina-Olsson, B. Muchmore, W. Tang et al., “A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus,” Nature Genetics, vol. 45, no. 2, pp. 164–171, 2013. View at Publisher · View at Google Scholar · View at Scopus
  14. S. Bibert, T. Roger, T. Calandra et al., “IL28B expression depends on a novel TT/-G polymorphism which improves HCV clearance prediction,” Journal of Experimental Medicine, vol. 210, no. 6, pp. 1109–1116, 2013. View at Publisher · View at Google Scholar · View at Scopus
  15. Y. Nozawa, T. Umemura, Y. Katsuyama et al., “Genetic polymorphism in IFNL4 and response to pegylated interferon-α and ribavirin in Japanese chronic hepatitis C patients,” Tissue Antigens, vol. 83, no. 1, pp. 45–48, 2014. View at Publisher · View at Google Scholar · View at Scopus
  16. S. Nakamoto, T. Kanda, F. Imazeki et al., “Simple assay based on restriction fragment length polymorphism associated with IL28B in chronic hepatitis C patients,” Scandinavian Journal of Gastroenterology, vol. 46, no. 7-8, pp. 955–961, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. H. Kumada, J. Toyota, T. Okanoue, K. Chayama, H. Tsubouchi, and N. Hayashi, “Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan,” Journal of Hepatology, vol. 56, no. 1, pp. 78–84, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. T. Hara, N. Akuta, F. Suzuki et al., “A pilot study of triple therapy with telaprevir, peginterferon and ribavirin for elderly patients with genotype 1 chronic hepatitis C,” Journal of Medical Virology, vol. 85, no. 10, pp. 1746–1753, 2013. View at Publisher · View at Google Scholar · View at Scopus
  19. T. Kanda, F. Imazeki, Y. Yonemitsu et al., “Quantification of hepatitis C virus in patients treated with peginterferon-alfa 2a plus ribavirin treatment by COBAS TaqMan HCV test,” Journal of Viral Hepatitis, vol. 18, no. 7, pp. e292–e297, 2011. View at Publisher · View at Google Scholar · View at Scopus
  20. M. Omata, T. Kanda, M.-L. Yu et al., “APASL consensus statements and management algorithms for hepatitis C virus infection,” Hepatology International, vol. 6, no. 2, pp. 409–435, 2012. View at Publisher · View at Google Scholar · View at Scopus
  21. Y. Nozawa, T. Umemura, Y. Katsuyama et al., “Genetic polymorphism in IFNL4 and response to pegylated interferon-α and ribavirin in Japanese chronic hepatitis C patients,” Tissue Antigens, vol. 83, no. 1, pp. 45–48, 2014. View at Publisher · View at Google Scholar · View at Scopus
  22. H. Fujino, M. Imamura, Y. Nagaoki et al., “Predictive value of the IFNL4 polymorphism on outcome of telaprevir, peginterferon, and ribavirin therapy for older patients with genotype 1b chronic hepatitis C,” Journal of Gastroenterology, 2013. View at Publisher · View at Google Scholar · View at Scopus
  23. Y. Nagaoki, M. Imamura, Y. Kawakami et al., “Interferon lambda 4 polymorphism affects on outcome of telaprevir, pegylated interferon and ribavirin combination therapy for chronic hepatitis C,” Hepatology Research, 2014. View at Publisher · View at Google Scholar
  24. A. F. Stättermayer, R. Strassl, A. Maieron et al., “Polymorphisms of interferon-λ4 and IL28B-effects on treatment response to interferon/ribavirin in patients with chronic hepatitis C,” Alimentary Pharmacology and Therapeutics, vol. 39, no. 1, pp. 104–111, 2014. View at Publisher · View at Google Scholar · View at Scopus
  25. L. M. Real, K. Neukam, R. Herrero et al., “IFNL4 ss469415590 variant shows similar performance to rs12979860 as predictor of response to treatment against hepatitis C virus genotype 1 or 4 in Caucasians,” PLoS ONE, vol. 9, no. 4, Article ID e95515, 2014. View at Publisher · View at Google Scholar · View at Scopus
  26. O. J. Hamming, E. Terczyńska-Dyla, G. Vieyres et al., “Interferon lambda 4 signals via the IFNλ receptor to regulate antiviral activity against HCV and coronaviruses,” EMBO Journal, vol. 32, no. 23, pp. 3055–3065, 2013. View at Publisher · View at Google Scholar · View at Scopus
  27. O. Manuel, A. Wójtowicz, S. Bibert et al., “Influence of IFNL3/4 polymorphisms on the incidence of cytomegalovirus infection after solid-organ transplantation,” The Journal of Infectious Diseases, 2014. View at Publisher · View at Google Scholar
  28. E. G. Meissner, D. Bon, L. Prokunina-Olsson et al., “IFNL4-ΔG genotype is associated with slower viral clearance in Hepatitis C, genotype-1 patients treated with sofosbuvir and ribavirin,” Journal of Infectious Diseases, vol. 209, no. 11, pp. 1700–1704, 2014. View at Publisher · View at Google Scholar · View at Scopus